Oppenheimer Begins Coverage on Praxis Precision Medicines (NASDAQ:PRAX)
Analysts at Oppenheimer started coverage on shares of Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) in a research note issued on Monday, Marketbeat Ratings reports. The firm set an “outperform” rating and a $97.00 price target on the stock. Oppenheimer’s price objective would indicate a potential upside of 135.44% from the stock’s previous close. […]
Analysts at Oppenheimer started coverage on shares of Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) in a research note issued on Monday, Marketbeat Ratings reports. The firm set an “outperform” rating and a $97.00 price target on the stock. Oppenheimer’s price objective would indicate a potential upside of 135.44% from the stock’s previous close. […]
